Fragment-to-Lead Medicinal Chemistry Publications in 2023

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Biochemistry

Background:

• Fragment-to-lead (F2L) studies are crucial for identifying novel drug candidates.
• Annual reviews track progress and identify emerging trends in this field.
• The 2023 literature provides new insights into F2L methodologies and outcomes.

Purpose of the Study:

• To summarize successful fragment-to-lead (F2L) studies published in 2023.
• To analyze trends in target classes, screening methods, and fragment/lead properties.
• To identify innovations enhancing fragment-based drug discovery (FBDD).

Main Methods:

• Compilation and analysis of 17 F2L studies from 2023.
• Tabulated summary of relevant articles.
• Comparative analysis of 2023 data with historical FBDD trends (2015-2023).

Main Results:

• A comprehensive overview of 16 F2L articles published in 2023.
• Identification of key trends in target classes and screening approaches.
• Analysis of fragment and lead property trends over time.

Conclusions:

• The 2023 literature showcases significant advancements in FBDD.
• Innovations in NMR, virtual screening, fragment library design, and fragment linking are notable.
• These advancements are expected to further improve the success rate of FBDD.